AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...

Imagine a career in a field you can’t imagine. Dominique Constantini parlayed her commitment to immunology to meeting unmet ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

Gilead is becoming a victim of its own success in hepatitis, as an increasing number of patients have been cured with its therapies and those from rivals such as Merck & Co and AbbVie. With a ...

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...